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Abstract
Hepatic stellate cell (HSC) activation is a pivotal event in initiation and progression of hepatic
fibrosis and a major contributor to collagen deposition driven by transforming growth factor beta
(TGFβ). microRNAs (miRs), small non-coding RNAs modulating mRNA and protein expression,
have emerged as key regulatory molecules in chronic liver disease. We investigated differentially
expressed miRs in quiescent and activated HSCs to identify novel regulators of profibrotic TGFβ
signaling. miR microarray analysis was performed on quiescent and activated rat HSCs. Members
of the miR-17-92 cluster (19a, 19b, 92a) were significantly down-regulated in activated HSCs.
Since miR 19b showed the highest fold-change of the cluster members, activated HSCs were
transfected with miR 19b mimic or negative control and TGFβ signaling and HSC activation
assessed. miR 19b expression was determined in fibrotic rat and human liver specimens. miR 19b
mimic negatively regulated TGFβ signaling components demonstrated by decreased TGFβ
receptor II (TGFβRII) and SMAD3 expression. Computational prediction of miR 19b binding to
the 3’UTR of TGFβRII was validated by luciferase reporter assay. Inhibition of TGFβ signaling
by miR 19b was confirmed by decreased expression of type I collagen and by blocking TGFβ-
induced expression of α1(I) and α2(I) procollagen mRNAs. miR 19b blunted the activated HSC
phenotype by morphological assessment and decreased αSMA expression. Additionally, miR 19b
expression was markedly diminished in fibrotic rat liver compared to normal liver; similarly, miR
19b expression was markedly down-regulated in fibrotic compared to normal human livers.
CONCLUSIONS—miR 19b is a novel regulator of TGFβ signaling in HSCs suggesting a
potential therapeutic approach for hepatic fibrosis.
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Fibrosis of the liver is characterized by excessive deposition of extracellular matrix (ECM)
components, predominantly type I collagen. Disproportionate deposition of fibrillar
collagens disrupts normal liver architecture and hepatic function, and if left untreated,
progresses to cirrhosis. Cytokine signaling predominates during fibrogenesis initiating
activation of resident immune and hepatic stellate cells (HSCs) promoting wound repair(1).
Activated HSCs are the principal cell type promoting synthesis and deposition of ECM
proteins in response to increased levels of circulating inflammatory signals derived from
damaged parenchymal cells. These resident vitamin A storing cells are found within the
perisinusoidal space of Disse in a quiescent state, but upon hepatic injury, HSCs
transdifferentiate into myofibroblast-like cells marked by expression of smooth muscle-α
actin (αSMA)(2), loss of retinyl ester stores and neural marker glial fibrillary acidic protein
(GFAP)(2-3), and increased proliferation and contractility. Myofibroblastic HSCs respond to
and secrete a variety of profibrogenic cytokines including connective tissue growth factor,
tissue inhibitor of metalloproteinases and transforming growth factor-β (TGFβ). Of these,
TGFβ is recognized as the most potent fibrogenic cytokine regulating HSC collagen
production via autocrine and paracrine signaling(4). TGFβ signal transduction plays a critical
role in establishment of the myofibroblast phenotype, as it directly up-regulates hallmarks of
HSC activation propelling the disease state forward(5-7). Inhibition of TGFβ receptors
(soluble TGFβRII and knockout models) and/or signaling components decreases HSC
activation and dramatically blunts chronic hepatic wound-healing in experimental animal
models(8-9). In addition to induction of TGFβ signaling, numerous morphological and gene
expression profile changes are acquired during transdifferentiation(10).
microRNAs (miRNAs, miRs) are small non-coding RNAs which negatively regulate target
gene expression through base pairing with 3’UTRs inducing mRNA cleavage or
translational repression. With multiple and diverse targets, miRNAs exert control over key
cellular developmental processes including differentiation and proliferation. Specific
contribution of select miRNAs in hepatic disease development and progression has been
described(11). Recent studies report the process of HSC transdifferentiation is governed by
differential miRNA expression. Specifically, down-regulation of miRNAs that control fat
accumulation and adipocyte programming and up-regulaton of miRNAs that promote
sustained activation of the cell concurrent with increased proliferation and suppression of
apoptotic responses are observed(12-14). Forced expression of miRs 150 and 194 in activated
HSCs resulted in suppression of the fibrotic phenotype and inhibition of ECM production
through downstream regulators of collagen expression(15). Additional studies by Ogawa et
al. reported direct regulation of collagen synthesis via binding of miR 29b to the 3’UTR of
collagen and transcriptional regulator SP1 in a human HSC line(16). While the field
continues to advance, studies to date have lacked accurate miRNA profiling of the divergent
HSC phenotypes in primary cells. Additionally, no studies have identified any miRs that
have a global effect on profibrotic TGFβ signaling in the liver which could be more efficient
than targeting a single gene.
Herein, we report a set of differentially expressed miRNAs in quiescent (freshly isolated) vs
activated HSCs, among which, miRNA 19b (miR 19b) directly inhibited fibrotic TGFβ
signaling. Specifically, we validated computational prediction of miR 19b binding to the
3’UTR of TGFβRII by luciferase reporter assay. miR 19b mimic significantly decreased
expression of TGFβRII as well as downstream target gene collagen, with additional
suppression of HSC activation (αSMA) and concurrent increases in quiescent
characteristics. In vitro findings translated to in vivo studies with decreased levels of miR
19b evident in fibrotic rat and human liver tissue compared to normal controls. These results
identify miR 19b as a novel regulator of TGFβ signaling in HSC-mediated fibrogenesis and
suggest a potential therapeutic approach for treating hepatic fibrosis.
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miRNA Isolation, Purification and Microarray
Total RNA was isolated from samples using Trizol Reagent (Invitrogen, Carlsbad, CA) per
manufacturer's instructions. RNA integrity was verified by an Agilent 2100 Bioanalyzer
profile (Agilent Technologies Inc., Santa Clara, CA). miRNA purification and microarray
details are described in the Supplementary Materials and Methods.
Primary Cell Isolation, Culture and Imaging
Male Sprague Dawley rats (> 500g; Charles River Laboratories, Wilmington, MA) were
used for these studies. All experiments were reviewed and approved by Carolinas Medical
Center Institutional Animal Care and Use Committee. Primary rat HSCs were isolated by
pronase/collagenase perfusion digestion followed by subsequent density gradient
centrifugation as previously reported(17). Cell purity (>95%) and viability were confirmed
by autofluorescence and trypan blue staining. HSCs were maintained in Dulbecco's modified
Eagle medium supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin and
100 μg/mL streptomycin. Culture medium was replaced every 48 hours unless otherwise
described and cells incubated at 37°C with 5% CO2. To document morphological changes,
representative images were captured using an Olympus IX71 microscope (Olympus
America Inc., Center Valley, PA). Primary rat hepatocytes were isolated and cultured as
previously described(18).
Quantitative Real-Time Polymerase Chain Reaction and Immunoblotting
qRT-PCR reactions and immunoblotting details are described in the Supplementary
Materials and Methods.
Transient Transfection
Activated HSCs (day 6) were transfected with mature miR 19b mimic and negative control
probes (scramble, SCR) (Dharmacon, Inc.; Lafayette, CO) using Lipofectamine 2000
(Invitrogen; Carlsbad, CA) according to manufacturer's instructions. Transient transfection
details are described in the Supplementary Materials and Methods.
Immunocytochemistry and In Situ Hybridization
Prior to transfection culture-activated HSCs were seeded onto glass coverslips. Cells were
transfected as described and fixed with 4% paraformaldehyde and stained with anti αSMA
antibody (Millipore, Billerica, MA) as previously described(19). Liver tissues were obtained
from the following fibrotic models: bile duct-ligation (BDL)/sham [Schrum lab, unpublished
data], and ethanol/lipopolysaccharide(20). Sections (6μm) were cut from paraffin embedded
tissues (RNase free). In situ hybridization was performed using mercury LNA™ detection
probes, 5’-DIG and 3’-DIG labeled miR 19b according to manufacturer's instructions
(Exiqon, Woburn, MA). To determine successful HSC activation in liver injury models,
paired immunohistochemistry staining for quiescent and activated markers was performed
(Supplementary Fig. S1).
Human Tissue Samples
Human fibrotic (Metavir fibrosis score of 3 or 4) liver biopsy samples (n=21) were obtained
from the Liver-Biliary-Pancreatic Program Repository at Carolinas Medical Center
(Charlotte, NC). The biopsies were being performed for clinical investigations. The consent
was for a small portion of the biopsies (1-4 mg wet weight) to be stored for research studies.
Samples were obtained under a protocol approved by the Institutional Review Board of
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CMC. All subjects provided written informed consent. Normal controls (n=7) were obtained
from the Liver Tissue Cell Distribution Center (LTCDS) specimen bank (Minneapolis, MN).
Statistical Analysis
Data are presented as mean ± SE as determined from at least three independent experiments
unless otherwise stated. Statistical analyses were performed using one way analysis of
variance or Student's t-test or Mann-Whitney rank sum test where appropriate. p < 0.05 was
considered significant, and denoted by *.
Results
miRNA Profiling in Quiescent and Activated Hepatic Stellate Cells
A total of 55 significantly differentially expressed miRs were identified by array analyses of
quiescent (freshly isolated) and activated (day 14 of culture) HSCs (Fig. 1A). Validation of
previously described miR expression levels was obtained, with miRs 16, 29a/b/c, 150 and
194 all significantly down-regulated during culture activation (Fig. 1A,B). These
experiments also identified ~20 differentially expressed miRs not previously reported in
published array data available at the time of manuscript preparation (data not shown).
Analysis of differentially expressed miRs revealed members of the miR-17-92 cluster (19a,
19b, 92a) were significantly down-regulated in the profibrotic activated phenotype (Fig.
1B). Based upon previous literature and in silico analyses (TargetScan and miRanda
prediction databases), which predict putative seed match sites for miR 19b in the 3’UTR of
TGFβRII, this miR was selected for further analysis. qRT-PCR confirmed array data,
verifying a significant decrease of miR 19b in activated compared to quiescent HSCs (Fig.
1C). Expression profile of miR 19b and predicted target mRNA TGFβRII were followed
over 14 days in culture and a significant inverse relationship was observed (Fig. 1D) with a
dramatic decrease seen in expression of the miR from quiescence to day 3 and a significant
up-regulation of TGFβRII.
miR 19b Negatively Regulates Profibrotic TGFβ Signaling
Activated HSCs were transfected with miR 19b (19b) or a miRNA mimic negative control
(scramble, SCR) and following 24 or 48 h of transfection, RNA and protein were analyzed.
Preliminary studies validated the SCR sequence did not significantly affect TGFβRII
expression or invariant control β-actin compared to mock transfection or untransfected cells
(Lipofectamine 2000 alone) (data not shown). Additionally, effective transfection of primary
cells was verified by qRT-PCR and consistent concentration dependent increases were
observed in miR 19b relative to 4.5S rRNA expression (Supplementary Fig. S2). TGFβRII
mRNA levels at both 24 and 48 h post-transfection were significantly decreased compared
to SCR control, with greatest reduction seen when transfected with 75 nM 19b (Fig. 2A,B).
Similar results were observed in human HSCs (LX-2) (Supplementary Fig. S3). Protein
expression of the receptor was also significantly blunted by forced expression of miR 19b
(Fig. 2C).
Fibrotic TGFβ signaling propagates through the SMAD family of transcriptional activators,
and like TGFβRII, SMAD2 and SMAD3 are up-regulated following fibrotic liver injury(21).
Down-regulation of TGFβ signaling can impact expression of downstream SMAD3 and
SMAD7(22-23). While SMAD2/3 3’UTRs do not harbor putative miR 19b binding sites (as
predicted by TargetScan and miRanda), mRNA expression of SMAD3 is significantly
down-regulated after 48 h of miR 19b transfection (Fig. 2D). miR 19b is also predicted to
bind to the 3’UTR of Co-SMAD4, but no significant changes were observed in SMAD4
mRNA expression following transfections (Supplementary Fig. S4). More importantly, to
determine whether downstream TGFβ signaling was impacted by disrupting TGFβRII,
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phosphorylation of SMAD3 was assessed. Compared to SCR, cells transfected with miR
19b showed a marked decrease in p-SMAD3 (Fig. 2E). Computational prediction of miR
19b binding to the 3’UTR of TGFβRII was validated by luciferase reporter assay using
LX-2 cells (Fig. 3). These cells were selected to achieve higher transfection efficiency than
primary rat HSCs. Addition of miR 19b mimic induced a 50-60% reduction in luciferase
activity compared to controls.
miR 19b Decreases Expression of TGFβ Target Genes
Effects of increasing miR 19b on downstream TGFβ signaling target procollagen mRNA
and protein were measured. Forced expression of miR 19b dampened mRNA expression of
both procollagen Col α1(I) and Col α2(I), with more significant effects observed on the
transcription of Col α2(I) (Fig. 4A,B). Translation of the fibrillar collagen is also markedly
decreased after 48 h of miR 19b treatment as denoted by decreased intracellular protein
expression (Fig. 4C), confirming negative regulation of TGFβRII signaling by miR 19b as
both procollagen 3’UTRs lack predicted binding sites (TargetScan). Additionally, functional
secretion of this protein is disrupted by miR 19b as determined by immunoblot utilizing
proteins concentrated from harvested culture medium (48 h) (Supplementary Fig. S5).
miR 19b Inhibits Paracrine TGFβ Signals
Recombinant TGFβ was added to day 6 culture-activated HSCs transfected with miR 19b
mimic and levels of procollagen mRNA determined. After 48 h Col α1(I) and α2(I) mRNA
expression was decreased even in the presence of exogenous TGFβ as compared to
respective control (Fig. 5), indicating a powerful role for miR 19b in the inflammatory
hepatic microenvironment. Additionally, as TGFβRII has been shown to modulate TGFβ
expression(24), miR 19b suppressed TGFβ1 expression as compared to control
(Supplementary Fig. S6A,B).
HSC Transdifferentiation is Regulated by miR 19b
Forced expression of miR 19b blunted the day 6 culture-activated HSC phenotype as
denoted by shrunken cytoplasm, decreased polygonal shape and increased spindle shaped
cellular protrusions (characteristic of the quiescent phenotype) (Supplementary Fig. S7).
Morphological changes indicative of suppression of the activated phenotype correlated with
levels of αSMA mRNA, which were significantly decreased after 48 h of transfection (Fig.
6A). Immunoctyochemical analysis of αSMA protein (as a marker of activated HSCs)
expression corroborated the visible reduction in activated phenotype as visualized by
markedly reduced red fluorescence as well as by disorganization and disorientation of actin
fibers (Fig. 6B). Further, miR 19b restored GFAP expression, a marker of quiescent HSCs
(Fig. 6C).
miR 19b is Decreased Following Fibrotic Liver Injury in vivo
Next, we assessed whether decreased miR 19b also occurs in vivo (or in intact animals), in a
rat model of hepatic fibrosis. Tissue sections from sham operated control and BDL rats were
subjected to in situ hybridization and qRT-PCR experiments to assess expression of miR
19b. miR 19b was markedly decreased in fibrotic liver tissue compared to controls (Fig.
7A,B). miR 19b specific staining (red fluorescence, Fig. 7A; blue chromagen,
Supplementary Fig. S8) in control tissue appears outside of the parenchymal cells and higher
magnification inspection is indicative of perisinusoidal (HSC-specific location) expression.
Supporting in situ hybridization data, low expression of miR 19b, comparable to that of
activated HSCs, were observed in primary rat hepatocytes as compared to quiescent HSCs
(Supplementary Fig. S9). To confirm initial observation of HSC specific expression, co-
localization of miR 19b (red fluorescence) and quiescent HSC specific marker (GFAP, green
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fluorescence) was performed. Merged images (Fig. 7C) obtained from single channel images
(Supplementary Fig. S10) showed high intensity yellow fluorescence in Sham tissue
indicating miR 19b expression in quiescent HSCs. As expected, decreased yellow
fluorescence was observed in BDL tissue (Fig. 7C). Interestingly, the decrease of miR 19b
observed in hepatic injury does not appear to be stimulus-specific, as another rat model of
liver injury/fibrosis (ethanol/lipopolysacchardide, ELPS(20)) also showed decreased hepatic
miR 19b levels (Supplementary Fig. S11), strengthening the conserved importance of
decreased miR 19b in hepatic fibrosis.
Human Hepatic Fibrosis is Associated with Altered miR 19b Expression
To determine if miR 19b expression is also affected in human hepatic fibrosis, total RNA
was isolated from fibrotic (Metavir fibrosis score of 3 or 4 due to varying etiologies
including PBC, HCC and HCV) and normal control livers. qRT-PCR was used to determine
relative expression levels of miR 19b. As observed in the rodent fibrotic injury models,
levels of miR 19b were also significantly decreased by approximately 80% in human
patients with fibrotic livers (Fig. 8A). Recent studies have shown inverse correlations
between tissue and plasma miR levels(25-26). miR 19b levels were assessed in the sera of
fibrotic patients, and when directly compared to pair-matched tissue levels, a clear inverse
relationship was observed (Fig. 8B).
Discussion
This study provides the first evidence that miR 19b has a functional role in rat and human
liver fibrosis. Mechanistically, miR 19b acts as a novel inhibitor of fibrotic TGFβ signaling
in the HSC and holds clinical promise as a therapeutic molecule and/or biomarker for
fibrosis. Significant down-regulation of miR 19b was observed in activated HSCs as well as
in rodent models of fibrosis and in human disease. Forced expression of mature miR 19b in
activated HSCs significantly reduced expression of TGFβRII through direct binding to the
3’UTR, which is vital for efficient activation of downstream profibrotic gene expression.
Although miR 19b levels were increased substantially at lower mimic concentrations
(Supplementary Fig. S2), it is not surprising that higher concentrations were necessary to
have a physiological effect as other factors may also modulate TGFβ signaling.
Additionally, since observations were made in a fibrotic phenotype, higher expression of
miR 19b (compared to quiescent) is likely needed to suppress TGFβRII expression.
Expression of procollagen mRNAs and secreted type I collagen were also markedly reduced
by miR 19b, even in the presence of exogenous TGFβ. As firmly established in the
literature, disruption of TGFβ signaling impedes HSC activation and fibrosis as evidenced
by altered expression of transdifferentiation markers (i.e. decreased aSMA and increased
GFAP)(2, 8-9, 27). miR 19b mediated-down-regulation of TGFβRII impeded HSC activation
and produced reversion to a more quiescent phenotype, and since αSMA and GFAP do not
harbor putative miR 19b binding sites, this effect is likely attributed to disruption of
profibrotic TGFβ signaling.
Although pathologies of chronic hepatic disease (ALD, HCV, HCC) are variable, TGFβ-
mediated fibrosis is an underlying commonality(28). TGFβ is the most potent stimulus for
HSC-mediated fibrogenesis(28-29) as it plays a critical role in initiation of the
transdifferentiation process. In addition to paracrine sources of the cytokine, TGFβ synthesis
is markedly increased by the HSC as a result of activation, further perpetuating the fibrotic
phenotype. Inhibition of TGFβ receptors, specifically TGFβRII, abrogates the signaling
pathway and HSC activation(5-7). These findings have established HSC-mediated TGFβ
signaling as a pivotal mechanism in hepatic fibrogenesis and disruption of HSC activation
and collagen deposition via inhibition of TGFβ signaling as a mechanism to ameliorate and/
or reverse fibrosis.
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miRs have emerged as key regulatory molecules in chronic liver disease, including hepatic
fibrosis(30-32). Array profiling studies report differential miR expression in normal vs.
fibrotic liver tissue in a variety of rodent injury models including BDL and carbon
tetrachloride (CCl4) (33). miRs 150, 187, 194 and 207 were significantly down-regulated in
HSCs isolated from BDL animals compared to sham controls, while let7 family members
were significantly up-regulated. Recently we have seen evidence that these small non-
coding RNAs modulate fibrogenesis and HSC activation(11). Overexpression of miRs 150
and 194 in human HSCs (LX-2) resulted in inhibition of proliferation as well as decreases in
type I collagen and αSMA(15).
miR profiling in human and murine liver fibrosis, and additional published in vitro
manipulation studies, have highlighted a role for the miR 29 family in fibrosis via regulation
of collagen expression(16, 33). While fibrosis underlies most chronic liver diseases, including
HCV and ALD, when expression of miR 29 was examined in human samples, Roderburg et
al. found expression of the miR highly variable amongst patients with viral vs alcohol-
induced fibrosis, indicating the role of miR 29 in fibrosis may be stimulus specific(33). Here
we report that miR 19b levels are down-regulated in two experimental animal models of
hepatic fibrosis (BDL, ELPS), and these results were confirmed in fibrotic human patients
despite variable underlying etiologies (HBV, HCV, HCC, PBC), supporting a highly
conserved role of this miR in fibrosis. Moreover, success in identifying target genes of
dysregulated miRs in liver disease has been limited. Herein, we report that miR 19b binds
directly to the 3’UTR of TGFβRII inhibiting fibrotic HSC activation.
miR expression patterns are organ and tissue specific, making systemic miR targeting
problematic. However, recent reports have shown that miRs derived from the miR-17-92
cluster (including miR 19b) directly regulate TGFβ signaling in non-liver cell types,
including neuroblastoma cells(34) and colonocytes(35). Additionally, miR 19b levels are
down-regulated in fibrosis and ECM remodeling of other tissue/organs (pulmonary,
cardiac)(36-37), indicating a highly conserved role of miR 19b in TGFβ-mediated
fibrogenesis. While transcriptional regulation of miR17-92 cluster is mostly unknown,
studies have reported that transcription factors p53, NFκB and E2Fs can modulate
expression of this cluster(38-39). Additionally, several miRs are post-transcriptionally
regulated by TGFβ and nuclear accumulation of SMAD proteins(38, 40). As levels of TGFβ
are known to increase as a result of hepatic injury promoting fibrogenesis, it is important to
note this cytokine may affect disease pathology through HSC-mediated actions as well as
through affecting global miR processing/expression.
Currently there are no FDA-approved treatments for fibrosis. As the field of miR research is
rapidly developing, pioneering advances have emphasized critical changes in miR
expression profiles during development of fibrosis which regulate wound-healing
transcripts. While acknowledged that therapeutic modulation of single miRs in vivo has
aimed to inhibit expression via antisense oligos/antagomirs, miR over-expression strategies
are also ongoing and hold great promise to restore delicate genetic programs vital to normal
organ function. Adenoviral delivery of miR-17-92 cluster inhibited HCV replication in cell
culture propogated HCV(41). Additionally, recent reports in HCC demonstrate miR 26a
administration is capable of repressing tumorigenesis without significant systemic
effects(42). While we cannot definitively demonstrate loss of miR 19b expression is a cause
or consequence of fibrosis, our data indicate that over-expression of miR 19b may be a
useful therapeutic agent for TGFβ-mediated fibrosis.
In addition to therapeutic applications, miR 19b may also serve as an accurate biomarker of
liver fibrosis and/or HSC activation. Several studies in settings of chronic liver disease with
underlying fibrosis have shown strong correlations between specific miR expression patterns
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and responses to drug treatments as well as disease progression/prognostic outcome(11).
Plasma levels of miR 122 are elevated in both HBV and HCV patients as well as in models
of alcohol and drug-induced liver damage reinforcing a role for miRs as biomarkers(26).
Recent studies have also shown inverse correlations between tissue and plasma miR
levels(25-26). In fact, miR 19b was up-regulated 4.3-fold in serum of individuals with
cirrhotic livers compared to normal controls(43) suggesting a potentially non-invasive route
for diagnosing hepatic fibrosis. In support of existing literature(43), despite the small sample
size, higher expression of miR 19b was evident in the sera compared to pair-matched tissue
of fibrotic patients. Future studies are needed to carefully monitor plasma miR 19b
expression in relation to tissue from healthy individuals compared to varying fibrotic stages
and etiologies.
HCV represents the major cause of hepatic fibrosis on a global scale and is the most
frequent indication of liver transplantation(44); however, recurrent hepatitis C occurs in 80%
of patients by 3 year post-transplant(45) and up to 20% advance to bridging fibrosis or
cirrhosis within 2 years(46) due to TGFβ signaling and HSC activation (47-48). Antiviral
therapy with interferon and ribavirin in transplant recipients is only 10-30% effective, and
therapy may not be well-tolerated. Identifying liver transplant recipients at greatest risk for
rapid development of fibrosis from recurrent hepatitis C would target those recipients most
urgently in need of antiviral therapy and defer treatment to those at less risk for disease
progression(48). In support of our findings, miR 19b levels were significantly higher in HCV
responder vs non-responder patient populations, underscoring the importance of this specific
miR. Examining expression levels of miR 19b in HCV transplant patients could lead to
development of a reliable marker to identify rapid progressors of fibrosis.
Overall these systematic studies indicate miR 19b is a novel regulator of fibrotic TGFβ
signaling and indicates the loss of miR 19b following HSC activation perpetuates the
fibrotic response. Restored miR 19b expression in activated HSCs indicated this miR may
be a possible therapy for the treatment or reversion of fibrosis, and patient data indicates this
powerful miR may prove to be an accurate biomarker for the fibrotic condition. These
studies provide novel insight into the global regulation of a key signaling pathway which
promotes hepatic fibrosis, and more importantly, provides a new avenue to be explored for
translational research.
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Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
ALD alcoholic liver disease
BDL bile duct-ligated
ECM extracellular matrix
GFAP glial fibrillary acidic protein
HCC hepatocellular carcinoma
HCV hepatitis C virus
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HSC hepatic stellate cell
IHC immunohistochemistry
miRNA microRNA
PBC primary biliary cirrhosis
qRT-PCR quantitative real time polymerase chain reaction
αSMA smooth muscle α-actin
TGFβ transforming growth factor beta
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Differential miRNA expression in quiescent vs activated HSCs. (A) Microarray analysis for
miRNA was performed with RNA extracts from primary quiescent (n=7) and activated
(n=6) HSCs. Hierarchical cluster analysis of significantly differentially expressed miRs:
bright green, underexpression; gray, no change; bright red, overexpression. (B) Listing of
differentially expressed miRs in the array analysis including p value and fold change. (C)
Rat HSCs were harvested and miR 19b expression was determined in quiescent (n=7) and
activated (day 14, n=6) HSCs as assessed by qRT-PCR. (D) qRT-PCR analysis of miR 19b
and TGFβRII expression levels over days in culture as normalized to 4.5S rRNA and β-
actin, respectively (n=3). Data are presented as mean ± SE. *Differs from quiescent, p<0.05.
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miR 19b negatively regulates TGFβRII expression. Day 6 HSCs were transiently transfected
with miR 19b mimic (25-75 nM) or miR mimic negative control (SCR), and TGFβRII gene
expression was measured by qRT-PCR at (A) 24 h and (B) 48 h (n=4). Expression was
normalized to β-actin. (C) Representative immunoblot of TGFβRII protein expression 48 h
post-transfection (miR 19b, 75 nM) (n=3). β-actin was used as an invariant control. (D)
SMAD gene expression in activated HSCs (day 6) transfected with mature miR 19b for 24
and 48 h was determined by qRT-PCR (n=3). (E) Representative immunoblot of
phosphorylated SMAD3 (p-SMAD3). β-actin was used as an invariant control. Data are
presented as mean ± SE. *Differs from SCR, p<0.05.
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miR 19b directly inhibits TGFβRII. Inhibition of firefly luciferase activities of pEZX-
TGFβRII reporter by miR 19b mimic. Human HSCs (LX-2) were co-transfected with 4.8 μg
of pEZX-TGFβRII reporter plasmid or empty vector and 75 nM miR 19b mimic or negative
miR mimic control (SCR) using Lipofectamine 2000 (n=3). Data are presented as mean ±
SE. *Differs from TGFβRII/SCR and CTRL/19b, p<0.05.
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miR 19b exerts inhibitory effects on TGFβ target gene collagen. Day 6 HSCs were
transiently transfected with miR 19b mimic (25-75 nM) or miR mimic negative control
(SCR) and Col α1(I) (A) and Col α2(I) (B) gene expression was assessed by qRT-PCR at
24 h (n=4). Expression was normalized to β-actin. (C) 48 h post-transfection cells were
harvested and immunoblot performed on whole cell lysates for type I collagen expression.
β-actin was used as an invariant control (n=3). Data are presented as mean ± SE. *Differs
from SCR, p<0.05.
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miR 19b inhibits paracrine TGFβ signals. Day 6 activated HSCs were transfected with or
without miR 19b mimic or miR mimic negative control (SCR) (75 nM), and following
standard 6 h incubation, transfection medium was removed and fresh culture medium devoid
of antibiotic was added containing 5 ng/mL of recombinant human TGFβ (TGFβ) for a
period of 48 h. Cells were harvested and mRNA levels of Col α1(I) and Col α2(I) were
assessed by qRT-PCR (n=3). Data are presented as mean ± SE. *Compared to SCR
alone, #compared to SCR, TGFβ, p<0.05.
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HSC transdifferentiation is regulated by miR 19b. (A) Activated HSCs (day 6) were
transfected with negative control (SCR) or miR 19b (75 nM) and αSMA gene expression
was assessed by qRT-PCR at 24 h and 48 h (n=4). (B) Representative images (40X) of
fluorescent immunocytochemical analysis of αSMA expression (red) in activated HSCs
following 48 h of transfection with SCR or miR 19b mimic (75 nM); DAPI staining (blue)
was used to indicate cell nuclei (n=3). (C) Day 6 HSCs were transiently transfected with
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miR 19b mimic or SCR (75 nM) and GFAP expression was assessed by qRT-PCR at 48 h
(n=4). Expression was normalized to β-actin. Data are presented as mean ± SE. *Differs
from SCR, p<0.05.
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Down-regulation of miR 19b in a rodent model of hepatic fibrosis. (A) Representative
immunofluorescent images of sham (normal) and BDL (fibrotic) tissue sections following in
situ hybridization with double DIG labeled LNA miR 19b probes. miR 19b expression
levels are marked by red fluorescence. Zonal damage (Z1, Z2, Z3) is indicated. (B) RNA
was harvested from sham (n=6) and BDL (n=6) tissues and miR 19b expression was
determined by qRT-PCR. (C) Co-localization of miR 19b (red fluorescence) and quiescent
HSC specific marker (GFAP, green fluorescence) was performed. Merged
immunofluorescent images (yellow fluorescence indicates quiescent HSCs expressing miR
19b) of sham and BDL tissue sections. Data are presented as mean ± SE. *Differs from
sham, p<0.05.
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miR 19b is a putative biomarker for human hepatic fibrosis. RNA was harvested from
normal (n=7) and fibrotic (n=21) human liver tissue (A) and sera (B; 6 pair-matched fibrotic
liver and sera samples) and miR 19b expression was assessed by qRT-PCR. Expression was
normalized to SNORD44 (A) and total cDNA (B). Data are presented as mean ± SE.
*Differs from control, p<0.05.
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